IGF-1 | Cases | Incidence rate per 1000 person-years | HR (95% CI) | ||
---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | |||
Dementia | |||||
Q1 | 1,419 | 1.24 (1.18–1.31) | 1.20 (1.11–1.30) | 1.17 (1.08–1.26) | 1.13 (1.05–1.22) |
Q2 | 1,144 | 1.00 (0.94–1.05) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Q3 | 1,171 | 1.02 (0.96–1.08) | 1.06 (0.97–1.15) | 1.07 (0.99–1.16) | 1.07 (0.99–1.16) |
Q4 | 1,123 | 0.98 (0.92–1.04) | 1.07 (0.98–1.16) | 1.09 (1.01–1.18) | 1.08 (1.00–1.17) |
Per 1-SD increment | |||||
IGF-1 < 18 nmol/L | 2,067 | 1.70 (1.63–1.78) | 0.61 (0.55–0.67) | 0.64 (0.58–0.71) | 0.69 (0.62–0.77) |
IGF-1 ≥ 18 nmol/L | 4,173 | 1.24 (1.21–1.28) | 1.26 (1.17–1.35) | 1.07 (1.02–1.12) | 1.06 (1.01–1.11) |
Stroke | |||||
Q1 | 1,757 | 1.54 (1.47–1.62) | 1.07 (1.00–1.15) | 1.04 (0.98–1.12) | 0.99 (0.93–1.06) |
Q2 | 1,618 | 1.41 (1.35–1.48) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Q3 | 1,453 | 1.27 (1.21–1.34) | 0.91 (0.85–0.98) | 0.92 (0.86–0.99) | 0.93 (0.87–1.00) |
Q4 | 1,412 | 1.24 (1.17–1.30) | 0.91 (0.85–0.98) | 0.92 (0.86–0.99) | 0.94 (0.87–1.01) |
Per 1-SD increment | |||||
IGF-1 < 26 nmol/L | 5,300 | 1.44 (1.40–1.48) | 0.87 (0.83–0.90) | 0.89 (0.86–0.92) | 0.93 (0.90–0.97) |
IGF-1 ≥ 26 nmol/L | 940 | 1.06 (0.99–1.13) | 1.11 (1.03–1.18) | 1.10 (1.03–1.18) | 1.09 (1.02–1.17) |
Parkinson's disease | |||||
Q1 | 416 | 0.36 (0.33–0.40) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Q2 | 478 | 0.41 (0.38–0.45) | 1.17 (1.03–1.33) | 1.18 (1.03–1.34) | 1.20 (1.05–1.37) |
Q3 | 548 | 0.48 (0.44–0.52) | 1.37 (1.21–1.56) | 1.38 (1.21–1.57) | 1.41 (1.24–1.60) |
Q4 | 674 | 0.59 (0.55–0.63) | 1.74 (1.54–1.97) | 1.76 (1.56–1.99) | 1.78 (1.57–2.01) |
Per 1-SD increment | 2,116 | 0.46 (0.44–0.48) | 1.23 (1.18–1.27) | 1.23 (1.18–1.28) | 1.23 (1.18–1.28) |